Identification of novel HLA‐A*11:01‐restricted CTL epitopes derived from the osteosarcoma antigen PBF

Abstract

Osteosarcoma is the most common malignancy of bone that affects young people. Neoadjuvant chemotherapy and surgery have significantly improved the prognosis. However, the prognosis of non‐responders to chemotherapy is still poor. To develop peptide‐based immunotherapy for osteosarcoma, we previously identified CTL epitopes derived from papillomavirus binding factor (PBF) in the context of HLA‐A2, HLA‐A24 and HLA‐B55. In the present study, we identified two novel CTL epitopes, QVT (QVTVWLLEQK) and LSA (LSALPPPLHK), in the context of HLA‐A11 using a sequence of screenings based on the predicted affinity of peptides, in vitro folding ability of a peptide/HLA‐A11 complex, reactivity of a peptide/HLA‐A11 tetramer and IFN‐γ production of T cells that was induced by mixed lymphocyte peptide culture under a limiting dilution condition. CTL clones directed to QVT and LSA peptides showed specific cytotoxicity against HLA‐A11⁺PBF⁺ osteosarcoma (HOS‐A11) cells. On the other hand, another epitope, ASV (ASVLSRRLGK), could highly induce cognate tetramer‐positive CTLs. This might be because the ASV peptide mimics the peptide ASV (R6Q) (ASVLSQRLGK) derived from bacterial polypeptides, ROK family proteins. However, ASV‐induced CTLs did not show cytokine production against the cognate peptide. In conclusion, the CTL epitopes QVT and LSA peptides might be useful for the development of immunotherapy targeting PBF for patients with osteosarcoma.

This article is protected by copyright. All rights reserved.

http://bit.ly/2BzH18X